News + Insight

News + Insight

News + Insight

Browse by category:

All

All

News

News

Insight

Insight

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Join our journey

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Join our journey

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Join our journey

Pløens Gate 7
Oslo, Norway 0176

Email

contact@alvb.no

Phone

+47 4067 1609

Our Solution

Market Opportunity

Our Solution

Science

About us

Our Story

Comparative Oncology

Board of Directors

Management

Quick Links

Home

Contact us

Privacy policy

News

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.

Pløens Gate 7
Oslo, Norway 0176

Email

contact@alvb.no

Phone

+47 4067 1609

Our Solution

Market Opportunity

Our Solution

Science

About us

Our Story

Comparative Oncology

Board of Directors

Management

Quick Links

Home

Contact us

Privacy policy

News

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.

Pløens Gate 7
Oslo, Norway 0176

Email

contact@alvb.no

Phone

+47 4067 1609

Our Solution

Market Opportunity

Our Solution

Science

About us

Our Story

Comparative Oncology

Board of Directors

Management

Quick Links

Home

Contact us

Privacy policy

News

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.